المؤلفون: Pardo-Montero, Juan, Pombar, Miguel, Gómez-Caamaño, Antonio, Giordanengo, Simona, González-Crespo, Isabel

مصطلحات موضوعية: Physics - Medical Physics

الوصف: Purpose: To present a methodology to analyze the variation of RBE with fractionation from clinical data of tumor control probability (TCP) and to apply it to study the response of prostate cancer to proton therapy. M&M: We analyzed the dependence of the RBE on the dose per fraction by using the LQ model and the Poisson TCP formalism. Clinical TCPs for prostate cancer treated with photon and proton therapy for conventional fractionation (2 Gy(RBE)x37 fractions), moderate hypofractionation (3 Gy(RBE)x20 fractions) and hypofractionation (7.25 Gy(RBE)x5 fractions) were obtained from the literature and analyzed. Results: The theoretical analysis showed three distinct regions with RBE monotonically decreasing, increasing or staying constant with the dose per fraction, depending on the change of ({\alpha}, \{beta}) values between photon and proton irradiation (the equilibrium point being at({\alpha}_p/\{beta}_p)=({\alpha}_X/\{beta}_X)({\alpha}_X/{\alpha}_p)). An analysis of the clinical data showed RBE values that decline with increasing dose per fraction: for low risk RBE=1.124, 1.119, and 1.102 for 1.82 Gy, 2.73 Gy and 6.59 Gy per fraction (physical proton doses), respectively; for intermediate risk RBE=1.119, and 1.102 for 1.82 Gy, and 6.59 Gy per fraction (physical proton doses), respectively. These values are nonetheless very close to the nominal 1.1 value. Conclusions: We presented a methodology to analyze the RBE for different fractionations, and we used it to study clinical data for prostate cancer. The analysis shows a monotonically decreasing RBE with increasing dose per fraction, which is expected from the LQ formalism and the changes in ({\alpha}, \{beta}) between photon and proton irradiation. However, the calculations in this study have to be considered with care as they may be biased by limitations in the modeling and/or by the clinical data set used for the analysis.
Comment: Minor changes to match accepted manuscript; in press Medical Physics

الوصول الحر: http://arxiv.org/abs/2303.09485Test

المؤلفون: Gago-Arias, Araceli, Neira, Sara, Pombar, Miguel, Gómez-Caamaño, Antonio, Pardo-Montero, Juan

المصدر: Radiotherapy and Oncology 2021;161:1-8

مصطلحات موضوعية: Physics - Medical Physics

الوصف: Background and purpose: To investigate the possible contribution of indirect damage and damage saturation to tumour control obtained with SBRT/SRS treatments for early-stage NSCLC and brain metastases. Methods and Materials: We have constructed a dataset of early-stage NSCLC and brain metastases dose-response. These data were fitted to models based on the linear-quadratic (LQ), the linear-quadratic-linear (LQL), and phenomenological modifications of the LQ-model to account for indirect cell damage. We use the Akaike-Information-Criterion formalism to compare performance, and studied the stability of the results with changes in fitting parameters and perturbations on dose/TCP values. Results: In NSCLC, a modified LQ-model with a beta-term increasing with dose yields the best-fits for $\alpha$/$\beta$=10 Gy. Only the inclusion of very fast accelerated proliferation or low $\alpha$/$\beta$ values can eliminate such superiority. In brain, the LQL model yields the best-fits, and the ranking is not affected by variations of fitting parameters or dose/TCP perturbations. Conclusions: For $\alpha$/$\beta$=10 Gy, a modified LQ-model with a beta-term increasing with dose provides better fits to NSCLC dose-response curves. For brain metastases, the LQL provides the best fit. This might be interpreted as a hint of indirect damage in NSCLC, and damage saturation in brain metastases. The results for NSCLC are strongly dependent on the value of $\alpha$/$\beta$ and may require further investigation, while those for brain seem to be clearly significant. Our results can assist in the design of improved radiotherapy for NSCLC and brain metastases, aiming at avoiding over/under-treatment.
Comment: Matches published version

الوصول الحر: http://arxiv.org/abs/2202.04953Test

المؤلفون: González-Crespo, Isabel, Gómez-Caamaño, Antonio, Pouso, Óscar López, Fenwick, John D., Pardo-Montero, Juan

المصدر: IEEE/ACM Transactions on Computational Biology and Bioinformatics 2023;20:808-821

مصطلحات موضوعية: Physics - Medical Physics, Physics - Biological Physics

الوصف: There is evidence of synergy between radiotherapy and immunotherapy. Radiotherapy can increase liberation of tumor antigens, causing activation of antitumor T-cells. This effect can be boosted with immunotherapy. Radioimmunotherapy has potential to increase tumor control rates. Biomathematical models of response to radioimmunotherapy may help on understanding of the mechanisms affecting response, and assist clinicians on the design of optimal treatment strategies. In this work we present a biomathematical model of tumor response to radioimmunotherapy. The model uses the linear-quadratic response of tumor cells to radiation (or variation of it), and builds on previous developments to include the radiation-induced immune effect. We have focused this study on the combined effect of radiotherapy and $\alpha$PDL1/$\alpha$CTLA4 therapies. The model can fit preclinical data of volume dynamics and control obtained with different dose fractionations and $\alpha$PDL1/$\alpha$CTLA4. A biomathematical study of optimal combination strategies suggests that a good understanding of the involved biological delays, the biokinetics of the immunotherapy drug, and the interplay between them, may be of paramount importance to design optimal radioimmunotherapy schedules. Biomathematical models like the one we present can help to interpret experimental data on the synergy between radiotherapy and immunotherapy, and to assist in the design of more effective treatments.
Comment: Matches accepted manuscript. Minor typos corrected. Extended Supplementary Materials

الوصول الحر: http://arxiv.org/abs/2106.07591Test

المؤلفون: Anido-Herranz, Urbano, Fernandez-Calvo, Ovidio, Ruiz-Bañobre, Juan, Martinez-Breijo, Sara, Fernandez-Nuñez, Natalia, Nogareda-Seoane, Zulema, Garrido-Pumar, Miguel, Casas-Nebra, Javier, Muñiz-Garcia, Gloria, Portela-Pereira, Paula, Gomez-Caamaño, Antonio, Perez-Fentes, Daniel Adolfo, Santome-Couto, Lucia, Lázaro, Martín, Molina-Diaz, Aurea, Medina-Colmenero, Ana, Vazquez-Estevez, Sergio

المصدر: Frontiers in Oncology ; volume 14 ; ISSN 2234-943X

الوصف: Introduction Radium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who are not candidates to receive it. In this study, we aimed to ambispectively analyze overall survival (OS) and prognostic features in mCRPC in patients receiving Ra-223 as per clinical routine practice and identify the most suitable treatment sequence. Patients and methods This study is observational, multicentric, and ambispective. Eligibility criteria included mCRPC patients treated with Ra-223, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, without visceral metastases, and no more than three cm involved lymph nodes. Results A total of 145 patients were included; the median age was 73.97 years, and a Gleason score of more than or equal to 7 in 61 (48%) patients; 73 (81%) had previously received docetaxel. The most important benefit was reached by those patients who received Ra-223 in the second-line setting, with a median OS of 17 months (95% CI, 12–21), and by patients who received six cycles of treatment, with a median OS of 19 months (95% CI, 14–21). An alkaline phosphatase (ALP) decrease was also identified as a prognosis marker. When performing the multivariate analysis, the time to develop castration-resistant disease longer than 24 months was the most important prognostic factor to predict the evolution of the patients receiving Ra-223. Ra-223 was well tolerated, with thrombocytopenia, anemia, and diarrhea being the main adverse events. Conclusion There is a benefit for those patients who received Ra-223 in the second-line setting, regardless of prior use of docetaxel. In addition, a survival benefit for patients presenting with a decline in ALP was observed.

الإتاحة: https://doi.org/10.3389/fonc.2024.1385466Test

المؤلفون: Wang, Anqi, Shen, Jiayi, Rodriguez, Alex A., Saunders, Edward J., Chen, Fei, Janivara, Rohini, Darst, Burcu F., Sheng, Xin, Xu, Yili, Chou, Alisha J., Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Plym, Anna, Sahimi, Ali, Hoffman, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Laisk, Triin, Figuerêdo, Jéssica, Muir, Kenneth, Ito, Shuji, Liu, Xiaoxi, Yamanashi, Yuji, Furukawa, Yoichi, Morisaki, Takayuki, Murakami, Yoshinori, Muto, Kaori, Nagai, Akiko, Obara, Wataru, Yamaji, Ken, Takahashi, Kazuhisa, Asai, Satoshi, Takahashi, Yasuo, Suzuki, Takao, Sinozaki, Nobuaki, Yamaguchi, Hiroki, Minami, Shiro, Murayama, Shigeo, Yoshimori, Kozo, Nagayama, Satoshi, Obata, Daisuke, Higashiyama, Masahiko, Masumoto, Akihide, Koretsune, Yukihiro, Uchio, Yuji, Kubo, Michiaki, Kamatani, Yoichiro, Lophatananon, Artitaya, Wan, Peggy, Andrews, Caroline, Lori, Adriana, Choudhury, Parichoy P., Schleutker, Johanna, Tammela, Teuvo L.J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Borge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Andreas, Stroomberg, Hein V., Batra, Jyotsna, Chambers, Suzanne, Horvath, Lisa, Clements, Judith A., Tilly, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordstrom, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui Yi, Albanes, Demetrius, Weinstein, Stephanie, Cook, Michael B., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie Élise, Stanford, Janet L., Ostrander, Elaine A., Koutros, Stella, Beane Freeman, Laura E., Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong Jie, Zhang, Hong Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M.L., Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Butler, Ebonee N., Mohler, James L., Taylor, Jack A., Kogevinas, Manolis, Dierssen-Sotos, Trinidad, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Pilie, Patrick, Yu, Yao, Bohlender, Ryan J., Gu, Jian, Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Brenner, Hermann, Chen, Xuechen, Holleczek, Bernd, Schöttker, Ben, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J.M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine M., Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Abraham, Aswin, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer, Petrovics, Gyorgy, Casey, Graham, Wang, Ying, Tettey, Yao, Lachance, Joseph, Tang, Wei, Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Yamoah, Kosj, Govindasami, Koveela, Chokkalingam, Anand P., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Shittu, Olayiwola, Amodu, Olukemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Diop, Halimatou, Gundell, Susan M., Roobol, Monique J., Jenster, Guido, van Schaik, Ron H.N., Hu, Jennifer J., Sanderson, Maureen, Kachuri, Linda, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Preuss, Michael H., Loos, Ruth J.F., Zawistowski, Matthew, Zöllner, Sebastian, Lu, Zeyun, Van Den Eeden, Stephen K., Easton, Douglas F., Ambs, Stefan, Edwards, Todd L., Mägi, Reedik, Rebbeck, Timothy R., Fritsche, Lars, Chanock, Stephen J., Berndt, Sonja I., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Gaziano, J. Michael, Justice, Amy C., Mancuso, Nick, Terao, Chikashi, Eeles, Rosalind A., Kote-Jarai, Zsofia, Madduri, Ravi K., Conti, David V., Haiman, Christopher A.

المصدر: Wang , A , Shen , J , Rodriguez , A A , Saunders , E J , Chen , F , Janivara , R , Darst , B F , Sheng , X , Xu , Y , Chou , A J , Benlloch , S , Dadaev , T , Brook , M N , Plym , A , Sahimi , A , Hoffman , T J , Takahashi , A , Matsuda , K , Momozawa , Y , Fujita , M , Laisk , T , Figuerêdo , J , Muir , K , Ito ....

مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, name=SDG 3 - Good Health and Well-being

الوصف: The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.

العلاقة: https://pure.eur.nl/en/publications/8163e0f1-562f-4b5a-91dd-048e427a9acaTest

الإتاحة: https://doi.org/10.1038/s41588-023-01534-4Test
https://pure.eur.nl/en/publications/8163e0f1-562f-4b5a-91dd-048e427a9acaTest
http://www.scopus.com/inward/record.url?scp=85176259299&partnerID=8YFLogxKTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841479/pdf/nihms-1939043.pdfTest

المؤلفون: Naderi, Elnaz, Aguado-Barrera, Miguel E, Schack, Line M H, Dorling, Leila, Rattay, Tim, Fachal, Laura, Summersgill, Holly, Martínez-Calvo, Laura, Welsh, Ceilidh, Dudding, Tom, Odding, Yasmin, Varela-Pazos, Ana, Jena, Rajesh, Thomson, David J, Steenbakkers, Roel J H M, Dennis, Joe, Lobato-Busto, Ramón, Alsner, Jan, Ness, Andy, Nutting, Chris, Gómez-Caamaño, Antonio, Eriksen, Jesper G, Thomas, Steve J, Bates, Amy M, Webb, Adam J, Choudhury, Ananya, Rosenstein, Barry S, Taboada-Valladares, Begona, Herskind, Carsten, Azria, David, Dearnaley, David P, de Ruysscher, Dirk, Sperk, Elena, Hall, Emma, Stobart, Hilary, Chang-Claude, Jenny, De Ruyck, Kim, Veldeman, Liv, Altabas, Manuel, De Santis, Maria Carmen, Farcy-Jacquet, Marie-Pierre, Veldwijk, Marlon R, Sydes, Matthew R, Parliament, Matthew, Usmani, Nawaid, Burnet, Neil G, Seibold, Petra, Symonds, R Paul, Elliott, Rebecca M, Bultijnck, Renée, Kerns, S.L., Vanneste, Ben

المصدر: Naderi , E , Aguado-Barrera , M E , Schack , L M H , Dorling , L , Rattay , T , Fachal , L , Summersgill , H , Martínez-Calvo , L , Welsh , C , Dudding , T , Odding , Y , Varela-Pazos , A , Jena , R , Thomson , D J , Steenbakkers , R J H M , Dennis , J , Lobato-Busto , R , Alsner , J , Ness , A , Nutting , C , Gómez-Caamaño , A , Eriksen , J G , Thomas , S ....

مصطلحات موضوعية: GWAS, Radiogenomics, SNP-based heritability, acute radiation-induced toxicity

الوصف: BACKGROUND: This study was designed to identify common genetic susceptibility and shared genetic variants associated with acute radiation-induced toxicity (RIT) across four cancer types (prostate, head and neck, breast, and lung). METHODS: A GWAS meta-analysis was performed using 19 cohorts including 12,042 patients. Acute standardized total average toxicity (rSTATacute) was modelled using a generalized linear regression model for additive effect of genetic variants adjusted for demographic and clinical covariates. LD score regression estimated shared SNP-based heritability of rSTATacute in all patients and for each cancer type. RESULTS: Shared SNP-based heritability of STATacute among all cancer types was estimated at 10% (se?=?0.02), and was higher for prostate (17%, se?=?0.07), head and neck (27%, se?=?0.09), and breast (16%, se?=?0.09) cancers. We identified 130 suggestive associated SNPs with rSTATacute (5.0x10-8

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/c91c501c-8567-4d35-bfe7-a72e7fb5d3d4Test

الإتاحة: https://doi.org/10.1093/jncics/pkad088Test
https://cris.maastrichtuniversity.nl/en/publications/c91c501c-8567-4d35-bfe7-a72e7fb5d3d4Test

المؤلفون: Heumann, Philipp, Aguado-Barrera, Miguel E., Avuzzi, Barbara, Azria, David, Briers, Erik, Bultijnck, Renée, Choudhury, Ananya, De Ruysscher, Dirk, Farcy-Jacquet, Marie-Pierre, Fonteyne, Valerie, Gómez Caamaño, Antonio, Helmbold, Irmgard, Johnson, Kerstie, Kerns, Sarah L., Lambrecht, Maarten, Lingard, Zoe, Rancati, Tiziana, Rosenstein, Barry S., Sperk, Elena, Paul Symonds, R., Talbot, Christopher, Valdagni, Riccardo, Vega, Ana, Veldeman, Liv, Ward, Tim, Webb, Adam, West, Catharine M., Chang-Claude, Jenny, Seibold, Petra

المصدر: RADIOTHERAPY AND ONCOLOGY ; ISSN: 0167-8140 ; ISSN: 1879-0887

مصطلحات موضوعية: Medicine and Health Sciences, Radiology, Nuclear Medicine and imaging, Oncology, Hematology, Radiotherapy, Prostate cancer, Patient -reported outcomes, Adverse events, Agreement

الوصف: Introduction: Previous studies showed that healthcare professionals and patients had only moderate to low agreement on their assessment of treatment-related symptoms. We aimed to determine the levels of agreement in a large cohort of prostate cancer patients. Methods: Analyses were made of data from 1,756 prostate cancer patients treated with external beam radiotherapy (RT) and/or brachytherapy in Europe and the USA and recruited into the prospective mul-ticentre observational REQUITE study. Eleven pelvic symptoms at the end of RT were compared after translating patient-reported outcomes (PROs) into CTCAE-based healthcare professional ratings. Gwet's AC2 agreement coefficient and 95% confidence intervals were calculated for each symptom. To compare severity of grading between patients and healthcare professionals, percent agreement and deviations for each symptom were graphically depicted. Stratified and sensitivity analyses were conducted to identify potential influencing factors and to assess heterogeneity and robustness of results.Results: The agreement for the 11 pelvic symptoms varied from very good (AC2 > 0.8: haematuria, rectal bleeding, management of sphincter control) to poor agreement (AC2 <= 0.2: proctitis and urinary urgency). Fatigue had a negative impact on the agreement. Patients tended to grade symptoms more severely than healthcare professionals. Information on sexual dysfunction was missing more frequently in healthcare professional assessment than PROs. Conclusion: Agreement was better for observable than subjective symptoms, with patients usually grad-ing symptoms more severely than healthcare professionals. Our findings emphasize that PROs should complement symptom assessment by healthcare professionals and be taken into consideration for clin-ical decision-making to incorporate the patient perspective.(c) 2022 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 176 (2022) 109426 This is an open access article under the CC BY-NC-ND license ...

وصف الملف: application/pdf

العلاقة: https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NPTest; http://hdl.handle.net/1854/LU-01GSA3TCNNBEGMM6V29JTV82NPTest; http://doi.org/10.1016/j.radonc.2022.11.015Test; https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NP/file/01GV3ES7SYPCDYS3C83JQD4M6ETest

الإتاحة: https://doi.org/10.1016/j.radonc.2022.11.015Test
https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NPTest
http://hdl.handle.net/1854/LU-01GSA3TCNNBEGMM6V29JTV82NPTest
https://biblio.ugent.be/publication/01GSA3TCNNBEGMM6V29JTV82NP/file/01GV3ES7SYPCDYS3C83JQD4M6ETest

المؤلفون: Calvo Manuel, Felipe Ángel, n. 1955, Gómez Caamaño, Antonio, Ferrer Albiach, Carlos, Rubio Rodríguez, María del Carmen, Conde Moreno, Antonio José, Giralt López Sagredo, Jorge Luis, Serrano Andreu, Francisco Javier, Aristu Mendióroz, José Javier

مصطلحات موضوعية: Oncología, Terapéutica

الوصف: An RANM. 2023;140(03):233-251

وصف الملف: application/pdf; [19] p. : il

العلاقة: http://bibliotecavirtual.ranm.es/ranm/es/consulta/registro.do?id=101591Test; http://bibliotecavirtual.ranm.es/ranm/es/catalogo_imagenes/grupo.do?path=1006587Test

الإتاحة: http://bibliotecavirtual.ranm.es/ranm/es/consulta/registro.do?id=101591Test
http://bibliotecavirtual.ranm.es/ranm/es/catalogo_imagenes/grupo.do?path=1006587Test

المؤلفون: Joseph, Nuradh, Cicchetti, Alessandro, McWilliam, Alan, Webb, Adam, Seibold, Petra, Fiorino, Claudio, Cozzarini, Cesare, Veldeman, Liv, Bultijnck, Renée, Fonteyne, Valérie, Talbot, Christopher J, Symonds, Paul R, Johnson, Kerstie, Rattay, Tim, Lambrecht, Maarten, Haustermans, Karin, De Meerleer, Gert, Elliott, Rebecca M, Sperk, Elena, Herskind, Carsten, Veldwijk, Marlon, Avuzzi, Barbara, Giandini, Tommaso, Valdagni, Riccardo, Azria, David, Jacquet, Marie-Pierre Farcy, Charissoux, Marie, Vega, Ana, Aguado-Barrera, Miguel E, Gómez-Caamaño, Antonio, Franco, Pierfrancesco, Garibaldi, Elisabetta, Girelli, Giuseppe, Iotti, Cinzia, Vavassori, Vittotorio, Chang-Claude, Jenny, West, Catharine M L, Rancati, Tiziana, Choudhury, Ananya

المساهمون: Joseph, Nuradh, Cicchetti, Alessandro, Mcwilliam, Alan, Webb, Adam, Seibold, Petra, Fiorino, Claudio, Cozzarini, Cesare, Veldeman, Liv, Bultijnck, Renée, Fonteyne, Valérie, Talbot, Christopher J, Symonds, Paul R, Johnson, Kerstie, Rattay, Tim, Lambrecht, Maarten, Haustermans, Karin, De Meerleer, Gert, Elliott, Rebecca M, Sperk, Elena, Herskind, Carsten, Veldwijk, Marlon, Avuzzi, Barbara, Giandini, Tommaso, Valdagni, Riccardo, Azria, David, Jacquet, Marie-Pierre Farcy, Charissoux, Marie, Vega, Ana, Aguado-Barrera, Miguel E, Gómez-Caamaño, Antonio, Franco, Pierfrancesco, Garibaldi, Elisabetta, Girelli, Giuseppe, Iotti, Cinzia, Vavassori, Vittotorio, Chang-Claude, Jenny, West, Catharine M L, Rancati, Tiziana, Choudhury, Ananya

مصطلحات موضوعية: fatigue, functional lo, integral dose, prostate cancer, radiotherapy - adverse effects

الوصف: IntroductionWe hypothesized that increasing the pelvic integral dose (ID) and a higher dose per fraction correlate with worsening fatigue and functional outcomes in localized prostate cancer (PCa) patients treated with external beam radiotherapy (EBRT). MethodsThe study design was a retrospective analysis of two prospective observational cohorts, REQUITE (development, n=543) and DUE-01 (validation, n=228). Data were available for comorbidities, medication, androgen deprivation therapy, previous surgeries, smoking, age, and body mass index. The ID was calculated as the product of the mean body dose and body volume. The weekly ID accounted for differences in fractionation. The worsening (end of radiotherapy versus baseline) of European Organisation for Research and Treatment of Cancer EORTC) Quality of Life Questionnaire (QLQ)-C30 scores in physical/role/social functioning and fatigue symptom scales were evaluated, and two outcome measures were defined as worsening in >= 2 (WS2) or >= 3 (WS3) scales, respectively. The weekly ID and clinical risk factors were tested in multivariable logistic regression analysis. ResultsIn REQUITE, WS2 was seen in 28% and WS3 in 16% of patients. The median weekly ID was 13.1 L center dot Gy/week [interquartile (IQ) range 10.2-19.3]. The weekly ID, diabetes, the use of intensity-modulated radiotherapy, and the dose per fraction were significantly associated with WS2 [AUC (area under the receiver operating characteristics curve) =0.59; 95% CI 0.55-0.63] and WS3 (AUC=0.60; 95% CI 0.55-0.64). The prevalence of WS2 (15.3%) and WS3 (6.1%) was lower in DUE-01, but the median weekly ID was higher (15.8 L center dot Gy/week; IQ range 13.2-19.3). The model for WS2 was validated with reduced discrimination (AUC=0.52 95% CI 0.47-0.61), The AUC for WS3 was 0.58, ConclusionIncreasing the weekly ID and the dose per fraction lead to the worsening of fatigue and functional outcomes in patients with localized PCa treated with EBRT.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36387203; info:eu-repo/semantics/altIdentifier/wos/WOS:000882506100001; volume:12; firstpage:1; lastpage:14; numberofpages:14; journal:FRONTIERS IN ONCOLOGY; https://hdl.handle.net/11579/149002Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85141666278

الإتاحة: https://doi.org/10.3389/fonc.2022.937934Test
https://hdl.handle.net/11579/149002Test

المؤلفون: Calleja-Escudero, Jesús, Barrondo, Víctor, Rodriguez-Alonso, Andrés, Gómez-Veiga, Francisco, Bestard, Joan, Gómez-Caamaño, Antonio, Grandoulier, Anne-Sophie, Pérez-Sampietro, Maria, Chantada-Abal, Venancio, Poza de Celis, Raúl

المصدر: Drugs Context ; ISSN:1745-1981 ; Volume:13

مصطلحات موضوعية: androgen deprivation, concomitant, hormone therapy, quality of life, radiotherapy

الوصف: Injectable extended-release formulations of luteinizing hormone-releasing hormone agonists (LHRHa) have simplified the treatment of prostate cancer with a satisfactory level of androgen castration. This study aims to determine the percentage of patients whose initial LHRHa prescription was renewed during follow-up, how many changed formulation and how their quality of life evolved.

العلاقة: https://doi.org/10.7573/dic.2024-2-2Test; https://pubmed.ncbi.nlm.nih.gov/38915919Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195525Test/

الإتاحة: https://doi.org/10.7573/dic.2024-2-2Test
https://pubmed.ncbi.nlm.nih.gov/38915919Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11195525Test/